Research graph
References from Drug survival of adalimumab across different manifestations of Behçet’s syndrome: a retrospective analysis in 335 patients. Local targets link to admitted publications; unresolved targets remain external evidence.
Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet’s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial
10.1016/s2665-9913(24)00194-2 · 2024 · External reference
Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet’s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial
10.1016/s2665-9913(24)00194-2 · 2024 · External reference
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial
10.1016/s0140-6736(16)31339-3 · 2016 · External reference
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial
10.1016/s0140-6736(16)31339-3 · 2016 · External reference
Adalimumab in patients with active noninfectious uveitis
10.1056/nejmoa1509852 · 2016 · External reference
Adalimumab in patients with active noninfectious uveitis
10.1056/nejmoa1509852 · 2016 · External reference
Adalimumab for the treatment of uveitis
10.1080/1744666x.2017.1288097 · 2017 · External reference
Adalimumab for the treatment of uveitis
10.1080/1744666x.2017.1288097 · 2017 · External reference
Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: national multicenter study of 177 cases
10.1002/art.41026 · 2019 · External reference
Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: national multicenter study of 177 cases
10.1002/art.41026 · 2019 · External reference
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet’s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial
10.1136/ard-2024-226113 · 2024 · External reference
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet’s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial
10.1136/ard-2024-226113 · 2024 · External reference
Adalimumab in the management of Behçet’s disease
2015 · External reference
Adalimumab in the management of Behçet’s disease
2015 · External reference
Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis
10.1001/jamadermatol.2022.2909 · 2022 · External reference
Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis
10.1001/jamadermatol.2022.2909 · 2022 · External reference
Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – a nationwide cohort study from the DANBIO and DERMBIO registries
10.1016/j.semarthrit.2022.151979 · 2022 · External reference
Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – a nationwide cohort study from the DANBIO and DERMBIO registries
10.1016/j.semarthrit.2022.151979 · 2022 · External reference
Anti-TNF-α therapy for refractory uveitis associated with Behçet’s syndrome and sarcoidosis: a single center study of 131 patients
10.1080/09273948.2020.1791346 · 2022 · External reference
Anti-TNF-α therapy for refractory uveitis associated with Behçet’s syndrome and sarcoidosis: a single center study of 131 patients
10.1080/09273948.2020.1791346 · 2022 · External reference
Long-term safety and efficacy of adalimumab for intestinal Behçet’s disease in the open label study following a phase 3 clinical trial
10.5217/ir.2017.15.3.395 · 2017 · External reference
Long-term safety and efficacy of adalimumab for intestinal Behçet’s disease in the open label study following a phase 3 clinical trial
10.5217/ir.2017.15.3.395 · 2017 · External reference
Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
10.1186/s12876-023-03090-x · 2023 · External reference
Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
10.1186/s12876-023-03090-x · 2023 · External reference
Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease
10.1016/j.cgh.2014.08.042 · 2015 · External reference
Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease
10.1016/j.cgh.2014.08.042 · 2015 · External reference
Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
10.3904/kjim.2022.394 · 2023 · External reference
Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
10.3904/kjim.2022.394 · 2023 · External reference
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study
10.1007/s10067-016-3417-4 · 2017 · External reference
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study
10.1007/s10067-016-3417-4 · 2017 · External reference
Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study
10.1136/bjophthalmol-2017-310733 · 2018 · External reference
Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study
10.1136/bjophthalmol-2017-310733 · 2018 · External reference
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
10.5217/ir.2020.00013 · 2021 · External reference
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
10.5217/ir.2020.00013 · 2021 · External reference
The safety and efficacy of TNF inhibitors in patients with Behçet’s disease: retrospective study from eastern Turkey
10.1016/j.clim.2024.110239 · 2024 · External reference
The safety and efficacy of TNF inhibitors in patients with Behçet’s disease: retrospective study from eastern Turkey
10.1016/j.clim.2024.110239 · 2024 · External reference
Long-term data on efficacy and safety of adalimumab in Behçet’s disease
10.1016/j.clim.2023.109242 · 2023 · External reference
Long-term data on efficacy and safety of adalimumab in Behçet’s disease
10.1016/j.clim.2023.109242 · 2023 · External reference
Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Behçet’s syndrome: a retrospective study of seventy patients with vascular involvement
10.1002/art.40531 · 2018 · External reference
Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Behçet’s syndrome: a retrospective study of seventy patients with vascular involvement
10.1002/art.40531 · 2018 · External reference
Brief report: drug-free long-term remission in severe Behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment
10.1002/art.40235 · 2017 · External reference
Brief report: drug-free long-term remission in severe Behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment
10.1002/art.40235 · 2017 · External reference
Very long-term remission in Behcet’s disease following withdrawal of anti-TNF treatment exceeds relapses: a reappraisal of an outcome study
10.1007/s00296-025-05806-6 · 2025 · External reference
Very long-term remission in Behcet’s disease following withdrawal of anti-TNF treatment exceeds relapses: a reappraisal of an outcome study
10.1007/s00296-025-05806-6 · 2025 · External reference
Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease
10.1016/j.ophtha.2018.02.020 · 2018 · External reference
Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease
10.1016/j.ophtha.2018.02.020 · 2018 · External reference
Real-world efficacy and safety of escalation to weekly adalimumab for chronic non-infectious uveitis: a multicenter study involving pediatric and adult patients
10.1080/09273948.2025.2456637 · 2025 · External reference
Real-world efficacy and safety of escalation to weekly adalimumab for chronic non-infectious uveitis: a multicenter study involving pediatric and adult patients
10.1080/09273948.2025.2456637 · 2025 · External reference
